Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENLV NASDAQ:IFRX NASDAQ:ORMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$0.82-3.8%$1.00$0.66▼$2.10$202.30M1.49548,720 shs243,375 shsIFRXInflaRx$1.97-7.5%$1.12$0.71▼$2.21$153.98M2.421.61 million shs1.19 million shsORMPOramed Pharmaceuticals$3.98+1.3%$3.57$1.98▼$4.22$158.95M1.27131,531 shs137,620 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics+0.47%-0.75%-13.89%-25.47%-21.17%IFRXInflaRx-6.19%+17.96%+115.91%+134.52%+19.39%ORMPOramed Pharmaceuticals0.00%-1.24%+16.37%+16.37%+72.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$0.82-3.8%$1.00$0.66▼$2.10$202.30M1.49548,720 shs243,375 shsIFRXInflaRx$1.97-7.5%$1.12$0.71▼$2.21$153.98M2.421.61 million shs1.19 million shsORMPOramed Pharmaceuticals$3.98+1.3%$3.57$1.98▼$4.22$158.95M1.27131,531 shs137,620 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics+0.47%-0.75%-13.89%-25.47%-21.17%IFRXInflaRx-6.19%+17.96%+115.91%+134.52%+19.39%ORMPOramed Pharmaceuticals0.00%-1.24%+16.37%+16.37%+72.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENLVEnlivex Therapeutics 2.00Hold$16.501,912.69% UpsideIFRXInflaRx 2.50Moderate Buy$5.80194.42% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest IFRX, ORMP, and ENLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026IFRXInflaRx OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.00 ➝ $5.004/21/2026IFRXInflaRx GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.004/7/2026ENLVEnlivex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.003/27/2026IFRXInflaRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/20/2026IFRXInflaRx GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $14.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENLVEnlivex TherapeuticsN/AN/AN/AN/A$8.15 per shareN/AIFRXInflaRx$30K4,747.04N/AN/A$0.65 per share3.03ORMPOramed Pharmaceuticals$2M80.50$0.09 per share43.32$5.02 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENLVEnlivex Therapeutics$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%N/AIFRXInflaRx-$51.63M-$0.76N/AN/AN/AN/A-80.51%-61.36%5/7/2026 (Estimated)ORMPOramed Pharmaceuticals$64.05M$1.492.67N/AN/AN/A-6.83%-6.25%N/ALatest IFRX, ORMP, and ENLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IFRXInflaRx-$0.17N/AN/AN/A$0.01 millionN/A3/27/2026Q4 2025ORMPOramed Pharmaceuticals-$0.08-$0.06+$0.02$0.24$0.50 millionN/A3/20/2026Q4 2025IFRXInflaRx-$0.17-$0.17N/A-$0.18$0.03 million($0.04) millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals$0.256.28%N/A16.78%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENLVEnlivex TherapeuticsN/A193.24193.24IFRXInflaRxN/A4.134.13ORMPOramed PharmaceuticalsN/A6.986.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENLVEnlivex Therapeutics1.02%IFRXInflaRx42.39%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipENLVEnlivex Therapeutics12.28%IFRXInflaRx16.30%ORMPOramed Pharmaceuticals17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENLVEnlivex Therapeutics70237.38 million208.23 millionOptionableIFRXInflaRx6072.29 million60.51 millionOptionableORMPOramed Pharmaceuticals1040.45 million33.25 millionOptionableIFRX, ORMP, and ENLV HeadlinesRecent News About These CompaniesOramed Pharmaceuticals IncorporatedApril 15, 2026 | edition.cnn.comOramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above 50-Day Moving Average - Here's What HappenedApril 7, 2026 | marketbeat.comOramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38March 27, 2026 | msn.comOramed: Q4 Earnings SnapshotMarch 26, 2026 | stamfordadvocate.comSLifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with OramedMarch 26, 2026 | finanznachrichten.deLifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to ProfitabilityMarch 13, 2026 | quiverquant.comQLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyMarch 13, 2026 | globenewswire.comOramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic TransactionJanuary 13, 2026 | finanznachrichten.deOramed and Lifeward Announce Strategic TransactionJanuary 13, 2026 | prnewswire.comLifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation CompanyJanuary 13, 2026 | globenewswire.comOramed stock rises after receiving $18 million payment from ScilexJanuary 7, 2026 | za.investing.comOramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend PaymentsJanuary 7, 2026 | prnewswire.comOramed Pharm completes warrant sale, boosting liquidityDecember 31, 2025 | msn.comWhy Oramed Pharmaceuticals Inc.’s (ORMP) Stock Is Up 7.03%December 25, 2025 | aaii.comAOramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After SetbackDecember 24, 2025 | seekingalpha.comORMP: Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan AdoptedNovember 24, 2025 | finance.yahoo.comThere Are Some Holes In Oramed Pharmaceuticals' (NASDAQ:ORMP) Solid Earnings ReleaseNovember 21, 2025 | finance.yahoo.comOramed Pharmaceuticals Inc.: Oramed Reports Fiscal Third Quarter 2025 Financial ResultsNovember 17, 2025 | finanznachrichten.deOramed Pharm Declares Dividend Amidst Takeover DefenseNovember 17, 2025 | msn.comOramed Reports Fiscal Third Quarter 2025 Financial ResultsNovember 17, 2025 | prnewswire.comORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTSNovember 17, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIFRX, ORMP, and ENLV Company DescriptionsEnlivex Therapeutics NASDAQ:ENLV$0.82 -0.03 (-3.80%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$0.82 +0.00 (+0.02%) As of 05:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.InflaRx NASDAQ:IFRX$1.97 -0.16 (-7.51%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.98 +0.01 (+0.25%) As of 06:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Oramed Pharmaceuticals NASDAQ:ORMP$3.98 +0.05 (+1.27%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$4.03 +0.05 (+1.13%) As of 06:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
